PPP1R13B and Myelodysplasia: Comparison of patient cohorts with de novo AML (n = 27) versus patients suffering from AML with myelodysplasia-related changes or post-cytotoxic therapy (n = 11) did show attenuated relative PPP1R13B mRNA expression levels in both cohorts, however with no significant differences between the groups (median expression 0.29 PPP1R13BdenovoAML vs. 0.38 PPP1R13Bs/tAML, p = 0.77), (Fig. 1D).